Search within Legislation

Search Results

No. S 68

Poisons Act

Poisons (Amendment) Rules 2000

In exercise of the powers conferred by section 20(1) of the Poisons Act, the Minister for Health hereby makes the following Rules:

Citation and commencement

1. These Rules may be cited as the Poisons (Amendment) Rules 2000 and shall come into operation on 1st March 2000.

Amendment of First Schedule

2. The First Schedule to the Poisons Rules (R 1) is amended —

(a)

by inserting, immediately above the item “Abciximab”, the following item:

“Abacavir; its salts; its esters; their salts”;

(b)

by inserting, immediately below the item “Abciximab”, the following item:

“Acamprosate; its salts”;

(c)

by inserting, immediately below the item “Adreno-corticotrophic hormone (ACTH)”, the following item:

“Alatrofloxacin; its salts; its esters; their salts”;

(d)

by inserting, immediately below the item “Azapropazone”, the following item:

“Azasetron; its salts”;

(e)

by inserting, immediately below the item “Boric acid; sodium borate”, the following item:

“Botulinum Toxin, when contained in preparations intended for treatment of human ailments”;

(f)

by inserting, immediately below the item “Brimonidine; its salts”, the following item:

“Brinzolamide”;

(g)

by inserting, immediately below the item “Buprenorphine; its salts”, the following item:

“Bupropion; its salts”;

(h)

by inserting, immediately below the item “Cefuroxime”, the following item:

“Celecoxib”;

(i)

by inserting, immediately below the item “Edrophonium; its salts”, the following item:

“Efavirenz”;

(j)

by inserting, immediately below the item “Embutramide”, the following item:

“Emedastine; its salts; its esters; their salts”;

(k)

by inserting, immediately below the item “Enoxaparin; its salts”, the following item:

“Entacapone”;

(l)

by inserting, immediately below the item “Epoprostenol; its salts”, the following items:

“Eprosartan; its salts; its esters; their salts

Eptifibatide”;

(m)

by inserting, immediately below the item “Flucytosine; its salts; its esters; their salts”, the following item:

“Fludarabine phosphate”;

(n)

by inserting, immediately below the item “Fosfestrol; its salts”, the following item:

“Fosfomycin; its salts; its esters and ethers; their salts”;

(o)

by inserting, immediately below the item “Ibacitabine”, the following item:

“Ibandronic acid; its salts”;

(p)

by inserting, immediately below the item “Lenograstim”, the following item:

“Lepirudin”;

(q)

by inserting, immediately below the item “Lovastatin”, the following item:

“Loxoprofen; its salts”;

(r)

by inserting, immediately below the item “Mafenide; its salts”, the following item:

“Mangafodipir; its salts”;

(s)

by inserting, immediately below the item “Milrinone; its salts”, the following item:

“Miltefosine”;

(t)

by inserting, immediately below the item “Moclobemide”, the following item:

“Moexipril; its salts”;

(u)

by inserting, immediately below the item “Niridazole”, the following item:

“Nisoldipine”;

(v)

by inserting, immediately below the item “Orciprenaline; its salts; when contained in aerosol dispensers”, the following item:

“Orlistat”;

(w)

by inserting, immediately below the item “Oxethazaine; its salts”, the following item:

“Oxidronic acid; its salts”;

(x)

by inserting, immediately below the item “Oxytocins, natural and synthetic”, the following item:

“Paclitaxel; which are intended for the treatment of human ailments”;

(y)

by inserting, immediately below the item “Promazine; its salts”, the following item:

“Promestriene”;

(z)

by inserting, immediately below the item “Quinine; its quarternary compounds, their salts”, the following item:

“Rabeprazole; its salts”;

(za)

by inserting, immediately below the item “Rafoxanide”, the following item:

“Raloxifene; its salts”;

(zb)

by inserting, immediately below the item “Rivastigmine; its salts; its esters; their salts”, the following item:

“Rizatriptan; its salts; its esters; their salts”;

(zc)

by inserting, immediately below the item “Rocuronium; its salts”, the following item:

“Rofecoxib”;

(zd)

by inserting, immediately below the item “Rolitetracycline; its salts; its esters; their salts”, the following item:

“Ropinirole; its salts”;

(ze)

by inserting, immediately below the item “Ropivacaine; its salts”, the following item:

“Rosiglitazone; its salts”;

(zf)

by inserting, immediately below the item “Teicoplanin”, the following item:

“Telmisartan”;

(zg)

by inserting, immediately below the item “Thyroxine; its salts”, the following item:

“Tianeptine; its salts”;

(zh)

by inserting, immediately below the item “Topotecan; its salts”, the following item:

“Toremifene; its salts; its esters; their salts”;

(zi)

by inserting, immediately below the item “Tranylcypromine; its salts”, the following items:

“Trastuzumab

Trazodone; its salts”;

(zj)

by inserting, immediately below the item “3, 4, 5-Trimethoxyamphetamine”, the following item:

“Trimetrexate; its salts; its esters; their salts”;

(zk)

by inserting, immediately below the item “Tropisetron; its salts”, the following item:

“Trovafloxacin; its salts; its esters; their salts”; and

(zl)

by inserting, immediately below the item “Zalcitabine”, the following item:

“Zanamivir”.

Amendment of Second Schedule

2. The Second Schedule to the Poisons Rules is amended —

(a)

by inserting, immediately below the second paragraph in the second column under the heading “Substance or article in which exempted” against the item “Antibiotics, the following, their salts; their esters:”, the following paragraph:

“Media containing antibiotics for storage of organs or tissues to be transplanted which are not intended for the treatment of human ailments.”;

(b)

by inserting, immediately below the item “Lignocaine; its salts”, the following items:

“Lithium Carbonate

Substances other than those intended for treatment of human ailments.

Lovastatin

Substances containing less than 1% of lovastatin. ”;

(c)

by inserting, immediately below the item “Sodium nitrite”, the following item:

“Theophylline; its salts; its derivatives; its compounds

Preparations containing 8-bromotheophylline compound with 2-amino-2-methyl-1-propranol (Pamabron).”; and

(d)

by deleting the item “Tranexamic acid” and its entries and substituting the following item:

“Tranexamic acid

Preparations containing not more than 0.05% of tranexamic acid.”.

Amendment of Third Schedule

3. The Third Schedule to the Poisons Rules is amended —

(a)

by inserting, immediately above the item “Abciximab”, the following item:

“Abacavir; its salts; its esters; their salts”;

(b)

by inserting, immediately below the item “Abciximab”, the following item:

“Acamprosate; its salts”;

(c)

by inserting, immediately below the item “Adreno-corticotrophic hormone (ACTH)”, the following item:

“Alatrofloxacin; its salts; its esters; their salts ”;

(d)

by inserting, immediately below the item “Azapropazone”, the following item:

“Azasetron; its salts”;

(e)

by inserting, immediately below the item “Boric acid; sodium borate”, the following item:

“Botulinum Toxin, when contained in preparations intended for treatment of human ailments”;

(f)

by inserting, immediately below the item “Brimonidine; its salts”, the following item:

“Brinzolamide”;

(g)

by inserting, immediately below the item “Buprenorphine; its salts”, the following item:

“Bupropion; its salts”;

(h)

by inserting, immediately below the item “Cefuroxime”, the following item:

“Celecoxib”;

(i)

by inserting, immediately below the item “Edrophonium; its salts”, the following items:

“Efavirenz

Emedastine; its salts; its esters; their salts”;

(j)

by inserting, immediately below the item “Enoxaparin; its salts”, the following item:

“Entacapone”;

(k)

by inserting, immediately below the item “Epoprostenol; its salts”, the following items:

“Eprosartan; its salts; its esters; their salts

Eptifibatide”;

(l)

by inserting, immediately below the item “Flucytosine; its salts; its esters; their salts”, the following item:

“Fludarabine phosphate”;

(m)

by inserting, immediately below the item “Fosfestrol; its salts”, the following item:

“Fosfomycin; its salts; its esters and ethers; their salts”;

(n)

by inserting, immediately below the item “Ibacitabine”, the following item:

“Ibandronic acid; its salts”;

(o)

by inserting, immediately below the item “Lenograstim”, the following item:

“Lepirudin”;

(p)

by inserting, immediately below the item “Lovastatin”, the following item:

“Loxoprofen; its salts”;

(q)

by inserting, immediately below the item “Mafenide; its salts”, the following item:

“Mangafodipir; its salts”;

(r)

by inserting, immediately below the item “Milrinone; its salts”, the following item:

“Miltefosine”;

(s)

by inserting, immediately below the item “Moclobemide”, the following item:

“Moexipril; its salts”;

(t)

by inserting, immediately below the item “Niridazole”, the following item:

“Nisoldipine”;

(u)

by inserting, immediately below the item “Orciprenaline; its salts; when contained in aerosol dispensers”, the following item:

“Orlistat”;

(v)

by inserting, immediately below the item “Oxedrine tartrate”, the following item:

“Oxidronic acid; its salts”;

(w)

by inserting, immediately below the item “Oxytocins, natural and synthetic”, the following item:

“Paclitaxel; which are intended for the treatment of human ailments”;

(x)

by inserting, immediately below the item “Promazine; its salts”, the following item:

“Promestriene”;

(y)

by inserting, immediately below the item “Quinine; its quarternary compounds, their salts”, the following item:

“Rabeprazole; its salts”;

(z)

by inserting, immediately below the item “Rafoxanide”, the following item:

“Raloxifene; its salts”;

(za)

by inserting, immediately below the item “Rivastigmine; its salts; its esters; their salts”, the following item:

“Rizatriptan; its salts; its esters; their salts”;

(zb)

by inserting, immediately below the item “Rocuronium; its salts”, the following item:

“Rofecoxib”;

(zc)

by inserting, immediately below the item “Rolitetracycline; its salts; its esters; their salts”, the following item:

“Ropinirole; its salts”;

(zd)

by inserting, immediately below the item “Ropivacaine; its salts”, the following item:

“Rosiglitazone; its salts”;

(ze)

by inserting, immediately below the item “Teicoplanin”, the following item:

“Telmisartan”;

(zf)

by inserting, immediately below the item “Thyroxine; its salts”, the following item:

“Tianeptine; its salts”;

(zg)

by inserting, immediately below the item “Topotecan; its salts”, the following item:

“Toremifene; its salts; its esters; their salts”;

(zh)

by inserting, immediately below the item “Tranylcypromine; its salts”, the following items:

“Trastuzumab

Trazodone; its salts”;

(zi)

by inserting, immediately below the item “3, 4, 5-Trimethoxyamphetamine”, the following item:

“Trimetrexate; its salts; its esters; their salts”;

(zj)

by inserting, immediately below the item “Tropisetron; its salts”, the following item:

“Trovafloxacin; its salts; its esters; their salts”; and

(zk)

by inserting, immediately below the item “Zalcitabine”, the following item:

“Zanamivir”.

[G.N. Nos. S 632/98; S 51/99; S 177/99; S 279/99]

Made this 16th day of February 2000.

MOSES LEE

Permanent Secretary,
Ministry of Health,
Singapore.

[PD(DAD) 78:1 Vol 3; AG/LEG/SL/234/97/1 Vol. 2]

(To be presented to Parliament under section 20(2) of the Poisons Act).